


C. MARK TANG



The Essential

BIOTECH INVESTMENT GUIDE

How to Invest in the Healthcare
Biotechnology and Life Sciences Sector



Contents

PREFACE	vii
ACKNOWLEDGEMENTS	ix
FIGURES AND TABLES	xviii
INTRODUCTION	1
BIOTECH STOCK FOR WEALTH GROWTH: AN ESSENTIAL PORTION OF ASSET ALLOCATION	1
<i>Biotechnological Innovation Benefits Society</i>	1
<i>Biotech Sector Outperforms</i>	1
<i>Strong Fundamentals and Product Pipelines</i>	2
<i>Strong Growth of Revenue and Profits</i>	6
<i>Biotechnology Differs from the Internet</i>	6
<i>Stock is Essential for Wealth Growth</i>	7
<i>Stock for Outpacing Inflation</i>	11
<i>Why Biotech?</i>	13
<i>Positive Demography: Our Baby Boomer Population</i>	15
<i>Positive Demographics Trend</i>	16
<i>Positive Technology Trend</i>	16
<i>Big Pharma and the Biotech Industry—Complementary to Each Other</i>	16
<i>Supply Demand Imbalance?</i>	20
CHAPTER 1	25
THE BASICS OF INVESTING	25
<i>The Case for Equities</i>	25
<i>The Rule of 72</i>	27
<i>The Power of Compounding</i>	28

<i>Opportunity Cost</i>	29
<i>Relationship Between Risk and Return</i>	29
<i>Dollar-Cost Averaging</i>	29
<i>Purchasing Power and Inflation—Is a CD Really Safe?</i>	31
<i>Holding Period and Risk</i>	32
<i>Understanding Risks</i>	33
<i>Diversification—Minimizing Your Investment Risk</i>	35
<i>Past Reasons for Not Investing</i>	38
<i>Historic Return and How Much Return One Should Expect</i>	39
<i>Technical Analysis</i>	39
<i>Investment Vehicles Available to Achieve Your Goals</i>	40
<i>Vehicle One: Stocks</i>	40
<i>Vehicle Two: Bonds</i>	44
<i>Vehicle Three: Cash</i>	45
<i>Vehicle Four: Mutual Funds</i>	45
<i>Vehicle Five: Unit Investment Trust</i>	46
<i>Vehicle Six: Managed Accounts</i>	47
<i>Vehicle Seven: Alternative Investment</i>	47
<i>Asset Allocation</i>	47
<i>Managing Your Portfolio and Wealth</i>	48
CHAPTER 2	51
AN INTRODUCTION TO BIOTECHNOLOGY AND GENOMICS	51
CHAPTER 3	63
UNDERSTANDING BIOTECHNOLOGY INVENTION AND THE FDA APPROVAL	
PROCESS	63
<i>Part I: Biotechnology Inventions and Patents</i>	63
<i>Part II: The FDA Approval Process for Drugs</i>	67
<i>Stages of the FDA Approval Process</i>	67
<i>Drug Review Glossary</i>	75
CHAPTER 4	79
INTRODUCTION TO BIOTECH INVESTING	79
<i>Value Investing</i>	79
<i>Growth Investing</i>	79
<i>The Industry Life Cycle</i>	80
<i>Characteristics of Investing in Biotech</i>	81
<i>Value Investing</i>	82
<i>Biotechnology Investment Trading Rules</i>	86
<i>Winning Biotechnology Company Attribute List</i>	89

CHAPTER 5	91
HOW TO VALUE AND INVEST IN A BIOTECH COMPANY	91
<i>Step One: The Economic and Business Cycle</i>	93
<i>Step Two: Industry Sector Analysis</i>	95
<i>Biotech Industry Sector Analysis</i>	95
<i>Step Three: Biotech Company Analysis</i>	97
<i>Valuation: Should I Buy This Biotech Stock Now?</i>	98
<i>Method 1: Relative Valuation</i>	100
<i>Comparisons of P/E Ratios</i>	102
<i>Method 2: Discounted Cash Flow (DCF) Analysis</i>	116
<i>Method 3: Sum-of-the-Parts Valuations</i>	116
<i>Method 4: Dividend Discount Model (DDM)</i>	119
<i>Method 5: Subscriber-Based Valuations</i>	119
<i>Method 6: Economic Value Added (EVA)</i>	120
<i>Method 7: Yield-Based Valuations—Valuing Market as an Example</i>	120
<i>Qualitative Component of the Valuation</i>	120
<i>Risks of Biotech Companies</i>	120
<i>Summary: Which Model Is Best for Valuing Biotech Companies?</i>	121
<i>Part II: Investing in Undervalued Healthcare Biotech—Proactive</i>	
<i>Value Investing in Healthcare™</i>	123
CHAPTER 6	131
INVESTING IN BIOTECHNOLOGY MUTUAL FUNDS	131
<i>Don't Put All Your Eggs in One Basket</i>	131
<i>Purchasing Power</i>	132
<i>Professional Management</i>	133
<i>Asset Allocation</i>	134
<i>Liquidity</i>	135
<i>Discipline</i>	135
<i>Dollar-Cost Averaging</i>	135
<i>The Case for Index Funds</i>	136
<i>Why Stock or Stock Mutual Funds?</i>	136
<i>The Cost of Delaying</i>	139
<i>The Benefits of Investing in Biotech Mutual Funds</i>	139
CHAPTER 7	145
HEALTHCARE BIOTECH INDEX INVESTING: STRATEGIES USING EXCHANGE-	
TRADED-FUNDS (ETFs), BIOTECH ISHARES, AND BOXES	145
<i>The Case for Index Funds</i>	145
<i>I. Exchange-Traded Funds (ETFs)</i>	146

<i>Advantages of ETFs</i>	147
<i>Options Strategies for Suitable Clients</i>	149
<i>Index-Linked ETFs</i>	150
<i>II. Index Investing</i>	151
<i>III. Strategies Using Biotech and Pharmaceutical BOXES</i>	152
CHAPTER 8	155
RISK MANAGEMENT CONSIDERATIONS FOR BIOTECH INVESTORS WITH CONCENTRATED EQUITY POSITIONS	155
<i>Alternative 1: Retention of the Position and Associated Risks</i>	156
<i>Alternative 2: Liquidation of the Position and Reinvestment of Net Proceeds</i>	158
<i>Alternative 3: Hedging, Monetizing, and Diversification Strategies</i>	158
<i>Conclusion</i>	159
<i>Glossary</i>	162
CHAPTER 9	163
MANAGING BIOTECH STOCK OPTIONS: YOUR EMPLOYEE BENEFITS	163
<i>Non-Qualified Biotech Options</i>	165
<i>Incentive Biotech Options</i>	166
<i>Your Biotech Option Plan</i>	167
<i>Alternative Biotech Stock Acquisition Programs</i>	170
<i>83(b) Election</i>	171
CHAPTER 10	175
AN INTRODUCTION TO HEALTHCARE BIOTECHNOLOGY HEDGE FUND INVESTING	175
<i>Hedge Fund Investment Styles</i>	176
<i>Three Ways to Participate Healthcare–Biotech Hedge Funds</i>	177
<i>Conduct Necessary Due Diligence Prior to Investing in Healthcare Hedge Fund</i>	178
<i>Conclusion</i>	179
CHAPTER 11	181
AN INTRODUCTION TO HEALTHCARE BIOTECHNOLOGY PRIVATE EQUITY INVESTING	181
<i>I. Healthcare Venture Capital</i>	182
<i>Four Investment Stages of Health Care–Biotech Venture Capital Funding</i>	183
<i>II. Healthcare Buyout Funds</i>	183

<i>III. Special Situations in Healthcare</i>	184
<i>Key Considerations</i>	184
<i>How to Participate in Private Equity Investing</i>	185
<i>Five Basic Ways To Participate in Healthcare Private Equity Investing</i>	186
<i>Measuring Performance of Healthcare Biotech Private Equity Funds</i>	187
<i>Conclusion</i>	188
CHAPTER 12	189
RETIREMENT PLANNING CONSIDERATIONS FOR BIOTECH EXECUTIVES AND INVESTORS	189
<i>Changing Careers: Affecting Your Retirement Savings</i>	189
<i>Direct And Indirect Rollovers: Spinning Your IRA</i>	190
<i>The Tax-Deferred Rollover</i>	192
<i>Retirement: Strategy</i>	192
CHAPTER 13	195
CHARITABLE DISPOSITION OF APPRECIATED BIOTECH STOCKS	195
<i>I. Private Foundations</i>	196
<i>II. Charitable Remainder Trusts</i>	197
<i>Conclusion</i>	198
<i>III. Alternative Charitable Gift Program Through National Philanthropic Trust (NPT)</i>	199
CHAPTER 14	201
MANAGING YOUR BIOTECH WEALTH—ESTATE PLANNING FOR BIOTECH INVESTORS, EXECUTIVES, AND FOUNDERS	201
<i>Other Trust Strategies to Minimize Estate Taxes</i>	208
<i>Conclusion</i>	213
EPILOGUE	215
APPENDIX A	217
WHAT IS TECHNICAL ANALYSIS?	217
<i>I. The Dow Theory</i>	217
<i>II. Four Groups of Technical Indicators</i>	218
<i>III. Top-Down Technical Analysis</i>	222
<i>IV. Reading Chart Patterns</i>	222
<i>Patterns Indicating a Reversal in a Stock Price Trend</i>	224
<i>Patterns Indicating a Consolidation in a Stock Price Trend</i>	224

APPENDIX B	229
BIOTECH AND LIFE SCIENCE GLOSSARY	229
<i>Glossary—Finance</i>	240
APPENDIX C	253
RESOURCES AND FURTHER READINGS	253
<i>Books</i>	253
<i>Web Sites</i>	254
<i>Newsletters</i>	254
<i>Newspapers and Magazines</i>	254
APPENDIX D	255
SPEAKING ENGAGEMENT REQUEST	255
INDEX	257